Nature Communications (Oct 2023)

Tripartite motif containing 26 prevents steatohepatitis progression by suppressing C/EBPδ signalling activation

  • Minxuan Xu,
  • Jun Tan,
  • Xin Liu,
  • Li Han,
  • Chenxu Ge,
  • Yujie Zhang,
  • Fufang Luo,
  • Zhongqin Wang,
  • Xiaoqin Xue,
  • Liangyin Xiong,
  • Xin Wang,
  • Qinqin Zhang,
  • Xiaoxin Wang,
  • Qin Tian,
  • Shuguang Zhang,
  • Qingkun Meng,
  • Xianling Dai,
  • Qin Kuang,
  • Qiang Li,
  • Deshuai Lou,
  • Linfeng Hu,
  • Xi Liu,
  • Gang Kuang,
  • Jing Luo,
  • Chunxiao Chang,
  • Bochu Wang,
  • Jie Chai,
  • Shengbin Shi,
  • Lianyi Han

DOI
https://doi.org/10.1038/s41467-023-42040-9
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 22

Abstract

Read online

Abstract Currently potential preclinical drugs for the treatment of nonalcoholic steatohepatitis (NASH) and NASH-related pathopoiesis have failed to achieve expected therapeutic efficacy due to the complexity of the pathogenic mechanisms. Here we show Tripartite motif containing 26 (TRIM26) as a critical endogenous suppressor of CCAAT/enhancer binding protein delta (C/EBPδ), and we also confirm that TRIM26 is an C/EBPδ-interacting partner protein that catalyses the ubiquitination degradation of C/EBPδ in hepatocytes. Hepatocyte-specific loss of Trim26 disrupts liver metabolic homeostasis, followed by glucose metabolic disorder, lipid accumulation, increased hepatic inflammation, and fibrosis, and dramatically facilitates NASH-related phenotype progression. Inversely, transgenic Trim26 overexpression attenuates the NASH-associated phenotype in a rodent or rabbit model. We provide mechanistic evidence that, in response to metabolic insults, TRIM26 directly interacts with C/EBPδ and promotes its ubiquitin proteasome degradation. Taken together, our present findings identify TRIM26 as a key suppressor over the course of NASH development.